2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Xanthine Oxidase

Xanthine Oxidase

XO

Xanthine Oxidase

Related Products

PDF 0.47 MB

Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.

Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N7150
    Tricetin 3',4',5'-trimethyl ether
    		Inhibitor 98%
    Tricetin 3',4',5'-trimethyl ether (5,7-Dihydroxy-3',4',5'-trimethoxyflavone) is a flavone glucoside, that can be isolated the flowers of Chrysanthemum sinensea. Tricetin 3',4',5'-trimethyl ether displays xanthine oxidase competitive-type inhibitory activity, with an IC50 of 0.51 μM and a Ki of 0.37 μM.
    Tricetin 3',4',5'-trimethyl ether
  • HY-14268S
    Febuxostat-d9
    		Inhibitor 98.70%
    Febuxostat-d9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with a Ki of 0.6 nM.
    Febuxostat-d<sub>9</sub>
  • HY-131268
    O-Desisobutyl-O-n-propyl Febuxostat
    		Inhibitor
    O-Desisobutyl-O-n-propyl Febuxostat, extracted from the patent CN 103467412, is an xanthine oxidase inhibitor.
    O-Desisobutyl-O-n-propyl Febuxostat
  • HY-B1135S
    Benzbromarone-d5
    		Inhibitor 99.42%
    Benzbromarone-d5 is deuterium labeled Benzbromarone.
    Benzbromarone-d<sub>5</sub>
  • HY-19657S
    Oxypurinol-13C,15N2
    		Inhibitor
    Oxypurinol-13C,15N2 is 15N and 13C labeled Oxypurinol (HY-19657). Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
    Oxypurinol-<sub>13</sub>C,<sub>15</sub>N<sub>2</sub>
  • HY-153968
    URAT1&XO inhibitor 1
    		Inhibitor 99.96%
    URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research.
    URAT1&XO inhibitor 1
  • HY-153972
    URAT1&XO inhibitor 2
    		Inhibitor 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
    URAT1&XO inhibitor 2
  • HY-14669
    Niraxostat
    		Inhibitor 98.54%
    Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved.
    Niraxostat
  • HY-167709
    Azacosterol
    		Inhibitor 99.85%
    Azacosterol (20.25-Diazacholesterol), also known as Diazasterol, acts as a DHCR24 inhibitor and initiates a cascade of reactions in cortical neurons after being administered orally or via intraperitoneal injection.
    Azacosterol
  • HY-14268A
    Febuxostat sodium
    		Inhibitor
    Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout.
    Febuxostat sodium
  • HY-162910
    HDAC-IN-79
    		Inhibitor
    HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
    HDAC-IN-79
  • HY-146273
    Xanthine oxidase-IN-7
    		Inhibitor
    Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout.
    Xanthine oxidase-IN-7
  • HY-151975
    Xanthine oxidoreductase-IN-5
    		Inhibitor 98.93%
    Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia.
    Xanthine oxidoreductase-IN-5
  • HY-150257A
    Xanthine oxidase-IN-11
    		Inhibitor
    Xanthine oxidase-IN-11 (XO8 analog) is an xanthine oxidase (XO) inhibitor.
    Xanthine oxidase-IN-11
  • HY-146297
    Xanthine oxidoreductase-IN-2
    		Inhibitor
    Xanthine oxidoreductase-IN-2 (Compound IVa) is a xanthine oxidoreductase (XOR) inhibitor with the IC50 of 7.2 nM. Xanthine oxidoreductase-IN-2 shows hypouricemic effects in mice.
    Xanthine oxidoreductase-IN-2
  • HY-174318
    NARS-3′
    		Inhibitor
    NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC50 of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.
    NARS-3′
  • HY-14874S
    Topiroxostat-d4
    		Inhibitor
    Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
    Topiroxostat-d<sub>4</sub>
  • HY-161455
    Xanthine oxidase-IN-13
    		Inhibitor
    Xanthine oxidase-IN-13 (Compound 10) is a selective xanthine oxidase inhibitor (IC50: 149.56 μM for bovine xanthine oxidase). Xanthine oxidase-IN-13 can be used for research of inflammatory arthritis.
    Xanthine oxidase-IN-13
  • HY-155123
    Antioxidant agent-13
    		Inhibitor
    Antioxidant agent-13 (Compound 5f) is an antioxidant agent. Antioxidant agent-13 inhibits DPPH and FRAP with IC50s of 80.33 and 85.69 μM. Antioxidant agent-13 also inhibits LOX and XO enzymes with IC50s of 16.85 and 23.01 μM.
    Antioxidant agent-13
  • HY-162961
    Xanthine oxidase-IN-16
    		Inhibitor
    Xanthine oxidase-IN-16 is potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 102 nM. Xanthine oxidase-IN-16 shows significant efficacy in hyperuricemia rats.
    Xanthine oxidase-IN-16
Cat. No. Product Name / Synonyms Application Reactivity